The EBMT-95 cohort included 402 patients who received DLT following allogeneic SCT. Treated were 223 patients with chronic myelogenous leukemia (CML) in 3 different phases of relapse. There were 97 patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) who received DLT. Smaller numbers of patients with acute lymphocytic leukemia (ALL) and multiple myeloma (MMY) were studied. Single patients with polycythemia vera and myeloproliferative syndrome (MPS) were also evaluated.

Patients surviving less than 30 days after DLT were excluded from analysis, leaving a cohort of 296 patients that was included in the evaluation of the frequencies of tumor responses, as defined by complete remission. Patients with chemotherapy responses were excluded; 14 patients with recurrent CML were excluded because of unknown relapse phase, and 7 patients with other diagnoses were also excluded (2 NHL, 1 juvenile CML, and 4 unknown).